Response to measles revaccination among toddlers in Saudi Arabia by the use of two different trivalent measles-mumps-rubella vaccines

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 93, Issue 2, 1999, Pages 214-219

  Khalil, M ^a,d   Poltera, A A ^b   Al Howasi, M ^a   Herzog, C ^b   Gerike, E ^c   Wegmuller B ^b   Gluck R ^b  

^a Suleimania Children's Hospital   (Saudi Arabia)

^b Berna Biotech AG   (Switzerland)

^c ROBERT KOCH INSTITUTE   (Germany)

^d STAT Advisory Medical Center   (Egypt)

Author keywords

Cell cultures; Edmonston Zagreb measles strain; Immunogenicity; Measles mumps rubella vaccines; Rubini mumps strain; Saudi Arabia; Tolerability; Vaccine regimens

Indexed keywords

MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; ENZYME IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; REVACCINATION; SAUDI ARABIA; SEROCONVERSION; VIRUS CULTURE;

AVES;

EID: 0032902625     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(99)90310-3     Document Type: Article

References (28)

1. American Academy of Pediatrics. Committee on Infectious Diseases (1998). Age for routine administration of the second dose of measles-mumps-rubella vaccine. Pediatrics, 101, 129-133.
2. Bartoloni, A., Cutts, F. T., Gugliemetti, P., Brown, D., Bianchi Bandinelli, M. L., Hurtado, H. & Roselli, M. (1997). Response to measles revaccination among Bolivian schoolaged children. Transactions of the Royal Society of Tropical Medicine and Hygiene, 91, 716-718.
3. Baughman, A. L., William, W. W., Atkinson, W. L., Cook, L. G. & Collins, M. J. (1994). The impact of college prematriculation immunisation requirements on risk for measles outbreaks. Journal of the American Medical Association, 272, 1127-1132.
4. Bland, J. & Clements, J. (1998). Protecting the world's children: the story of WHO'S immunization programme. World Health Forum, 19, 162-173.
5. Boulianne, N., De Serres, G., Ratnam, S., Ward, B. J., Joly, J. R. & Duval, B. (1995). Measles, mumps and rubella antibodies in children 5-6 years after immunisation: effect of vaccine type and age at vaccination. Vaccine, 13, 1611-1616.
6. Briss, P. A., Fehrs, L. J., Parker, R. A., Wright, P. F., Sannella, E. C., Hutcheson, R. H. & Schaffner, W. (1994). Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine induced immunity. Journal of Infectious Diseases, 169, 77-82.
7. Broliden, K., Abren, E. R., Arneborn, M. & Böttiger, M. (1998). Immunity to mumps before and after vaccination at 12 years of age in the first generation offered the two-dose immunisation progamme. Vaccine, 16, 323-327.
8. Cheek, J. E., Baron, R., Atlas, H., Wilson, D. L. & Crider, R. D. (1995). Mumps outbreak in a highly vaccinated school population. Archives of Pediatric and Adolescent Medicine, 149, 774-778.
9. Cochi, S. L., Wharton, M. & Plotkin, S. A. (1994). Mumps vaccine. In: Vaccine, Plotkin, S. A. & Mortimer, E. A. (editors), second edition. Philadelphia: Saunders Company, p. 288.
10. Cremer, N. E., Cossen, C. K., Shell, G., Diggs, J., Gallo, D. & Schmidt, N. J. (1985). Enzyme immunoassay versus plaque neutralisation and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses. Journal of Clinical Microbiology, 13, 869-874.
11. Cutts, F. T. & Markowitz, L. E. (1994). Successes and failures in measles control. Journal of Infectious Diseases, 170, (supplement 1), 32-44.
12. Forsey, T., Heath, A. B. & Minor, P. D. (1993). A European collaborative study to assess the proficiency of laboratory estimates of potency of live measles, mumps and rubella trivalent vaccines. Biologicals, 21, 239-249.
13. Gassner, M., Hess, U. & Berger, R. (1995). Mumps: efficacy of a booster dose. Schweizerische Medizinische Wochenschrift, 125, 2506-2510.
14. Goetz, O. & Peller, P. (1978). Antikörper gegen das Mumpsvirus bei Kindern und Erwachsenen. Monatsschrift der Kinderheilkunde, 126, 244-245.
15. 10 E-Z. Saudi Medical Journal, 14, 44-45.
16. Khalil, M. (1996). Manual of immunization for G.C.C. [Gulf Cooperation Council] states. Riyadh: Executive Board of the Health Minister's Council for G.C.C. States. January 1996.
17. Li-Volti, S., Giammanco-Bilancia, G., Grassi, M., Garozzo, R., Glück, R. & Giammanco, G. (1993). Duration of the immune response to MMR vaccine in children of two age-different groups. European Journal of Epidemiology, 9, 311-314.
18. Marufu, T., Siziya, S., Tshimanga, S., Murugasampillay, S. & Mason, E. (1997). Comparison of protection afforded by single measles vaccination and late revaccination schedules. East African Medical Journal, 74, 777-779.
19. Miller, E. & Gay, N. (1997). Effect of age on outcome and epidemiology of infectious diseases. Biologicals, 25, 137-142.
20. Miller, E., Hill, A., Morgan Capuer, P., Forsey, T. & Rush, M. (1995). Antibodies to measles, mumps and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine, 13, 799-802.
21. Minor, P. D. (1997). Laboratory tests of mumps vaccines. Biologicals, 25, 35-40.
22. Pachón, I. & Tormo, A.(1997). 1. Situación de la parotiditis en España durante 1996. Boletín Epidemiológico Semanal (Ministerio de Sanidad y Consume), 5, 13-20.
23. Peltola, H. (1997). Good performance of vaccination by education. Biologicals, 25, 237-239.
24. Peltola, H., Heinone, O. P., Valle, M., Paunio, M., Vitranen, M., Karanko, V. & Cantell, K. (1994). The elimination of indigenous measles, mumps and rubella from Finland by a 12 year, two dose vaccination program. New England Journal of Medicine, 331, 1397-1402.
25. Ratnam, S., Veerabhadra, G., West, R., Burris, J., Oates, E., Stead, F. & Bouilianne, N. (1995). Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. Journal of Clinical Microbiology, 33, 811-815.
26. Schwarzer, S., Reibel, S., Lang, A. B., Struck, M.-M., Finkel, B., Gerike, E., Tischer, A., Gassner, M., Glück, R., Stück, B. & Cryz, S. J. (1998). Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. Vaccine, 16, 298-308.
27. WHO (1997). Expanded Programme on Immunization (EPI). Measles and the interruption of indigenous transmission, 1996, United States of America. Weekly Epidemiological Record, 72, 181-184.
28. Zartarian, M. V., Friedly, G., Peterson, E. M. & de la Maza, L. M. (1981). Detection of rubella antibodies by hemagglutination inhibition, indirect fluorescent-antibody test, and enzyme-linked immunosorbent assay. Journal of Clinical Microbiology, 14, 640-645.